Seres Therapeutics Inc Stock News

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in the 43rd Annual J.P. Morgan Healthcare Conference. Eric Shaff, President and Chief Executive Officer, will present a corporate overview on January 16, 2025 at 7:30 a.m. PT.

CAMBRIDGE, Mass., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that Eric Shaff, President and Chief Executive Officer, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET.

Seres Therapeutics, Inc. (NASDAQ:MCRB ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Carlo Tanzi - Investor Relations Eric Shaff - Chief Executive Officer Lisa von Moltke - Chief Medical Officer Teresa Young - EVP, Chief Commercial & Strategy Officer, Marella Thorell - Chief Financial Officer Matthew Henn - EVP, Chief Scientific Officer Conference Call Part...

CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will host a conference call and live audio webcast on November 13, 2024 at 8:30 a.m. ET to discuss third quarter 2024 financial results and provide business updates.

Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biotherapeutics, for multiple medically vulnerable patient populations at high risk of life-threatening bacterial infections

GENEVA--(BUSINESS WIRE)--Lucien Selce and MKT Capital Ltd. (together, “we”), who collectively own 1.4 million shares of Seres Therapeutics Inc. (NASDAQ: MCRB) (“Seres” or the “Company”), today published the following open letter to the Company's Board of Directors (the “Board”). *** September 27, 2024 Members of the Board, We are writing to you today as a stockholder of Seres who is seeking add...

CAMBRIDGE, Mass., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (“Seres” or the “Company”), a leading live biotherapeutics company, today announced that its stockholders voted to approve the previously announced proposed sale of the Company's VOWST business to Société des Produits Nestlé S.A. Seres will file a Current Report on Form 8-K with the SEC which details t...

Seres Therapeutics' sale of VOWST to Nestlé extends its cash runway to Q4 2025, addressing near-term financial concerns. MCRB will receive a $100 million upfront payment, with approximately $20 million used to settle net obligations. It also gets potential future milestone payments of up to $275 million. Promising Phase 1b data for SER-155 shows potential in preventing bacterial infections in i...